Dynamics of preventive vs postdiagnostic cancer control using lowimpact measures
Abstract
Cancer poses danger because of its unregulated growth, development of resistance, and metastatic spread to vital organs. We currently lack quantitative theory for how preventive measures and postdiagnostic interventions are predicted to affect risks of a life threatening cancer. Here we evaluate how continuous measures, such as life style changes and traditional treatments, affect both neoplastic growth and the frequency of resistant clones. We then compare and contrast preventive and postdiagnostic interventions assuming that only a single lesion progresses to invasive carcinoma during the life of an individual, and resection either leaves residual cells or metastases are undetected. Whereas prevention generally results in more positive therapeutic outcomes than postdiagnostic interventions, this advantage is substantially lowered should prevention initially fail to arrest tumour growth. We discuss these results and other important mitigating factors that should be taken into consideration in a comparative understanding of preventive and postdiagnostic interventions.
https://doi.org/10.7554/eLife.06266.001eLife digest
About one person in every two will get cancer during their lives. Surgery and chemotherapy have long been mainstays of cancer treatment. Both, however, have substantial downsides. Surgery may leave behind undetected cancer cells that can grow into new tumours. Furthermore, in response to chemotherapy drugs, some cancer cells may emerge that resist further treatment. There is therefore interest in whether preventive strategies—including lifestyle changes and medications—could reduce the likelihood of confronting a lifethreatening cancer.
Now, Akhmetzhanov and Hochberg have developed a mathematical model to help compare the effectiveness of preventive strategies and traditional cancer treatments. The model—which assumes that a person can only develop a single cancer from a single region of precancerous cells—suggests that longterm cancer prevention strategies reduce the risk of a lifethreatening cancer by more than traditional treatment that begins after a tumour is discovered. The preventive measures may be less effective in some cases compared to traditional treatments if they initially fail to stop a tumour growing, although on average they still work better than treating the cancer after detection.
According to Akhmetzhanov and Hochberg's model, surgical removal followed by chemotherapy is less likely to be successful than prevention, and when successful, requires larger impacts on the cancer (and therefore creates more sideeffects for the patient) to achieve the same level of control as prevention. The model also suggests that even at very low levels of impact on residual cancer cells, chemotherapies are likely to be counterproductive by boosting the subsequent emergence of treatmentresistant tumours.
Akhmetzhanov and Hochberg's model predicts how effective preventive measures need to be in terms of slowing the growth of cancer cells to result in given reductions in the future risk of a lifethreatening cancer. Future work should test this model by measuring the effects on tumour growth of prevention and of traditional therapies.
https://doi.org/10.7554/eLife.06266.002Introduction
Mathematical models play an important role in describing and analysing the complex process of carcinogenesis. Natural selection for increases in tumour cell population growth can be represented as the net effect of increased cell division rates and/or decreased apoptosis (e.g., Wodarz and Komarova, 2007). Relatively rare driver mutations confer such a net growth advantage, whereas numerically dominant passenger mutations with initially neutral or mildly deleterious effects (Marusyk et al., 2012; Bozic et al., 2013; McFarland et al., 2013) can increase in frequency due to genetic hitchhiking or subsequent positive selection. Amongst the many passengers in a growing tumour, some can contribute to chemoresistance, and sufficiently large tumours could contain different clones that, taken as a group, can resist some, if not most, chemotherapies (see Michor et al., 2005 for resistance to imatinib). Chemotherapeutic remission followed by relapse suggests that these resistant cells are often present at low frequencies prior to therapy, either due to genetic drift or costs associated with resistance. Resistant phenotypes subsequently increase in frequency during radiotherapy or chemotherapy, and through competitive release they may incorporate one or more additional drivers, resulting in accelerated growth compared to the original tumour (for related discussion on pathogens, see Huijben et al., 2013).
Previous mathematical studies have considered alternatives to attempting to minimize or eradicate clinically diagnosed cancers with maximum tolerated doses (MTDs) of chemotherapeutic drugs. This body of work indicates that MTD is particularly prone to select for chemoresistance (e.g., Foo and Michor, 2009; Foo and Michor, 2010; Lorz et al., 2013), and what little empirical work exists supports this basic prediction (Turke et al., 2010), but see (Kouyos et al., 2014) for other disease systems. Numerous alternatives to the goal of cancer minimization/eradication have been proposed and investigated (e.g., Maley et al., 2004; Komarova and Wodarz, 2005; Foo and Michor, 2009; Gatenby et al., 2009a, 2009b; Bozic et al., 2013; Jansen et al., 2015). For example, Komarova and Wodarz (2005) considered how the use of one or multiple drugs could prevent the emergence or curb the growth of chemoresistance. They showed that the evolutionary rate and associated emergence of a diversity of chemoresistant lineages is a major determinant in the success or failure of multiple drugs vs a single one. Lorz and coworkers (Lorz et al., 2013) recently modelled the employment of cytotoxic and cytostatic therapies alone or in combination and showed how combination strategies could be designed to be superior in terms of tumour eradication or managing resistance than either agent used alone. Foo and Michor (2009) evaluated how different dosing schedules of a single drug could be used to slow the emergence of resistance given toxicity constraints. One of their main conclusions is that drugs slowing the generation of chemoresistant mutants and subsequent evolution are more likely to be successful than those only increasing cell death rates.
These and other computational approaches have yet to consider the use of preventive measures to reduce cancerassociated morbidity and mortality whilst limiting resistance. Prevention includes lifestyle changes and interventions or therapies in the absence of detectable invasive carcinoma (e.g., Etzioni et al., 2003; Lippman and Lee, 2006; William et al., 2009; Hochberg et al., 2013), for example, reduced cigarette consumption (Doll and Peto, 1976) or chemoprevention (Steward and Brown, 2013). In depth consideration of preventive measures and their likely impact on individual risk and epidemiological trends is important given the likelihood that all individuals harbour precancerous lesions, some of which may transform into invasive carcinoma (Bissell and Hines, 2011; Greaves, 2014), and concerns as to whether technological advances will continue to make significant headway in treating clinically detected cancers (Gillies et al., 2012; Vogelstein et al., 2013).
Here, we model how continuous, constant measures affect tumour progression and the emergence of resistant lineages. We assume that an individual can contract at most a single cancer, originating from a single lesion. Importantly, we consider cases where the measure may select for the evolution of resistant phenotypes and cases where no resistance is possible. Our approach is to quantify the daily extent to which a growing neoplasm must be arrested in order to either eradicate it or to delay a potentially lethal cancer. Several authors have previously argued how constant or intermittent low toxicity therapies either before or after tumour discovery could be an alternative to MTD chemotherapies (Wu and Lippman, 2011; Hochberg et al., 2013), but to our knowledge, no study has actually quantified based on empirical parameter estimates, the extent to which cancer cell population growth needs to be arrested for such approaches to succeed (see related discussion in Bozic et al., 2010; Gerstung et al., 2011; Bozic et al., 2013). Below we employ the terms ‘treatment’, ‘measure’, and ‘therapy’ interchangeably, all indicating intentional measures to arrest cancer cell population growth.
We first derive analytical expressions for the expected total number of cells within a tumour at any given time. We explore dynamics of tumour sizes at given times, and times to detection for given tumour sizes. Specifically, we show that the expected mean tumour size in a population of subjects can be substantially different from the median, since the former is highly influenced by outliers due to tumours of very large size. We then consider constant preventive measures and show that treatment outcome is sensitive to initial conditions, particularly for intermediatesized tumours. Importantly, we provide approximate conditions for tumour control both analytically and numerically using empirical parameter estimates. We next consider postdiagnostic interventions in which tumour resection either is not complete and leaves residual cells or undetected metastases are present. We contrast these with prevention scenarios where (1) there is no difference in the age at which either prevention or postdiagnostic intervention commences, and (2) prevention and postdiagnostic interventions are alternatives, that is, the former always occurs before the latter. We show as expected that therapeutic outcomes are generally superior under prevention vs postdiagnostic intervention, and that higher impacts on the cancer cell population are usually required for postdiagnostic interventions to achieve a level of control comparable to prevention. Moreover, we find that should resection leave sufficiently large numbers of residual cells (or metastases are not discovered), then a range of the most successful outcomes under prevention is not attainable under postdiagnostic intervention, regardless of potential cell arrest. Finally and importantly, whereas there is little gained in terms of outcomes in postdiagnostic intervention beyond approximately 0.3% cell arrest per day for both small (10,000) and large (1 million) cancer cell populations, prevention outcomes may achieve continual gains for the latter cell number, up to about 0.6% cell arrest per day.
Modeling framework
Previous study has evaluated the effects of deterministic and stochastic processes on tumour growth and the acquisition of chemoresistance (Komarova and Wodarz, 2005; Bozic et al., 2010; Reiter et al., 2013, see review Beerenwinkel et al., 2015). We first consider both processes through exact solutions and numerical simulations of master equations, using the mean field approach (see Appendix 1 for details). A mean field approach assumes a large initial number of cells (Krapivsky et al., 2010) and averages any effects of stochasticity, so that an intermediate state of the system is described by a set of ordinary differential equations (i.e., master equations; Gardiner, 2004). Solutions to these are complex even in the absence of the explicit consideration of both drivers and passengers (Antal and Krapivsky, 2011; Kessler and Levine, 2013).
We do not explicitly model the different precancerous or invasive carcinoma states. Rather, our approach follows the dynamics of the relative frequencies of subclones, each composed of identical cells (Baake and Wagner, 2001; Saakian and Hu, 2006). We simulate tumour growth using a discrete time branching process for cell division (Athreya and Ney, 1972; Bozic et al., 2010). For each numerical experiment, we initiate a tumour of a given size and proportion of resistant cells.
Briefly, the model framework is as follows. Each cell in a population is described by two characteristics. The first is its resistance status to the measure, which is either ‘not resistant’ (j = 0) or ‘resistant’ (j = 1). The second property is the number of accumulated driver mutations (maximum N) in a given cell line. At each time step of 4 days, cells either divide or die, and when a cell divides, its daughter cell has a probability $u$ of producing a driver mutation and v of producing a resistant mutation. We assume no back mutation, and that cells do not compete for space or limiting resources.
The fitness function f_{ij}, the difference between the birth and death rates of a cell, is defined by the number of accumulated drivers (i = 0, 1, …, N) and resistance status (j = 0, 1): a sensitive cancerous cell with a single driver has selective advantage s, and any accumulated driver adds s to fitness, while resistance is associated with a constant cost c. Exposure to a single treatment affects only nonresistant cells (j = 0), incurring a loss σ to their fitness. Thus, the fitness function is:
The assumption of driver additivity is a special case of multiplicative fitness, and both are approximately equivalent for very small s.
We conducted numerical experiments, each with the same initial states but each using a unique set of randomly generated numbers of a branching process. For each simulation and each time step, the number of cells at time (t + 1) was sampled from a multinomial distribution of cells at time t (see Bozic et al., 2010 for details). Table 1 presents baseline parameter values employed in this study. Hereafter, we refer to σ as the treatment intensity (applied once every cell cycle of 4 days), while the corresponding daily arrest level to nonresistant cells is approximated by σ/4.
Results
Preventive measures
We first study preventive interventions where a patient has a high risk of developing a cancer and/or a biomarker that indicates the probable presence of a cancer. In either case, so that we can compare and contrast different intervention levels, we assume that the (undetected) tumour contains M_{0} cells when prevention commences. We examine effects on the mean by considering the distribution of tumour sizes at different times using meanfield dynamics (see Appendix 1). Numerical experiments were then conducted by assuming that tumours initially contained M_{0} = 10^{6} identical cells (i = 0), of which 0.01% were resistant. These assumptions are obviously oversimplifications, and we relax some of them below and in the next sections.
There is an excellent correspondence between analytical and numerical results for σ varied in range of s (Appendix 1—figure 1A). A more detailed study of the distribution of tumour sizes reveals that the mean diverges considerably from median behaviour in the majority of cases, since the former is strongly influenced by outliers with hightumour cell numbers (see Appendix 1—figure 1B).
Figure 1 shows four examples of numerical experiments. An untreated tumour reaches the assumed detection threshold of 10^{9} cells by about 18 years on average and because it is not subject to strong negative selection (we assume low c), any emerging resistant celllines are likely to remain at low frequency (0.03% at the detection time in the example of Figure 1A). In Figure 1B, lowtreatment intensity delays tumour growth and thus time of detection by approximately 16 years, while an increase in dose tends to result in tumours dominated by resistant cells (Figure 1C). Despite being unaffected by treatment, resistant cell populations are sometimes observed to go extinct stemming from stochasticity (Figure 1D), and this tends to occur more at hightreatment levels, because there are fewer sensitive tumour cells to seed new (mutant) resistant cell populations.
We next considered how therapies affected the distribution of tumour detection times in cases where the cancer cell population attained a threshold of 10^{9} cells. The magnitude of the selective advantage s shows that tumour growth is largely driven by its nonresistant part for relatively lowimpact treatments σ < 2s (Figure 2A). Importantly, the tumour shifts from being mainly nonresistant to resistant at σ ≈ 2s, which is reflected by the inflection point in the trajectory of the median (indicated by point B in Figure 2A,B). Notice that detection times are also most variable at σ ≈ 2s. The median changes smoothly at hightreatment levels (σ > 2s), tending to a horizontal asymptote. This is explained by the fact that the sensitive part is heavily suppressed at hightreatment levels, meaning that the dynamics are strongly influenced by the actual time point at which the first resistance mutation occurs.
We find, counterintuitively, that earlydetected tumours are more likely to be resistant under constant treatments than those detected at later times (A, B, and C in Figure 2C). This is because tumours under treatment that by chance obtain resistance early grow faster than those that do not. By the time of detection, nonresistant tumours usually accumulate up to 4 additional drivers on average, while resistant tumours have fewer. For larger values of cost c, an additional nonregularity emerges at σ ≈ 3s (segment DEF in Figure 2B), and is associated with tumours having a majority of cells with maximum numbers of drivers. This region is also characterized by a different transition to complete resistance (cf. Videos 1, 2 for relatively low and high costs of resistance, respectively). For example, at point D, tumours with a majority of nonresistance have less variable detection times than tumours with a majority of resistant cells (points E and F in Figure 2B and corresponding panels in Figure 2C). Treatment levels along the segment DEF result in tumours that are more likely to be resistant as one goes from the centre to the tails of the distribution of detection times. This differs qualitatively from the previous case of a lower cost of resistance, where the tumours are less resistant in the tail of the distribution of detection times (cf segments ABC and DEF in Figure 2B and corresponding panels in Figure 2C).
The inflection point at σ ≈ 2s in Figure 2A is due to the accumulation of additional drivers within tumours and associated increases in the likelihood that the tumour eventually resists treatment. Since the initial population consists of 10^{6} cells, in the absence of treatment, a mutant cell with one additional driver and associated fitness 2s will appear very rapidly. Such a tumour can be suppressed only if σ > 2s. This is supported by additional numerical experiments where we vary the maximal number of additional driver mutations N: the inflection point σ ≈ 2s disappears when N = 0 (Figure 2—figure supplement 1A). The inflection points at σ = 3s, 4s emerge at treatment levels that effectively suppress sensitive subclones with the most drivers before resistance mutations are obtained (cf Figure 2—figure supplement 1A–C with Figure 2—figure supplement 1D and Video 3). Specifically, the peaked distributions, corresponding to better therapeutic outcomes, tend to disappear when resistant subclones emerge.
The initial cancer cell number M_{0} affects both the median and distribution of detection times (Figure 2—figure supplement 1B). For large initial tumours, growth is deterministic and exponential. As the initial size is decreased from 10^{6} to 10^{5}, stochastic effects are increasingly manifested by greater variability in tumour inhibition and an inflection point observed at the 95th percentile. Moreover, we find that a tumour is likely to be eradicated under a range of constant treatments when M_{0} = 10^{5} or fewer initial cells; in contrast, a tumour is virtually certain to persist regardless of treatment level for M_{0} = 10^{7} cells or greater (Figure 2—figure supplement 2A,B). In other words, our model indicates that tumours that are c. 1% the size of most clinically detectable, internal cancers will typically be impossible to eradicate by single molecule chemoprevention when resistance is possible.
Given the mutation rates assumed here, many tumours with 1 million cells will either already contain or rapidly subsequently acquire resistant cells (Iwasa et al., 2006). It is therefore not surprising that the initial fraction of resistant cells in a tumour has little impact on dynamics (Figure 2—figure supplement 1C). In contrast, another measure of success in control (the fraction of persons with tumours that remain undetected after 50 years of growth) improves substantially with lower numbers of initial resistance mutations, particularly at higher treatment levels (Figure 2—figure supplement 2C). This is because the initial phases of treatment have a major impact on the potential for new resistant mutants: should few be initially present or emerge, they will either go stochastically extinct or will not grow to detection levels (1 billion cells) in the 50 year time frame of these numerical experiments.
We conducted further sensitivity analyses by varying accumulation rates u of additional driver mutations. We find that tumours exhibit more or less deterministic growth depending on the initial number of cells M_{0} and driver mutation rate u whereby the larger the population (Figure 2—figure supplement 1B) or the higher the mutation rate (Appendix 1—figure 4A), the less apparent are stochastic effects. The corresponding analysis is presented in ’Varying mutation rate and initial tumour size‘ in Appendix 1 and Appendix 1—figure 4.
Finally, we considered scenarios where the cost of resistance is dosedependent and specifically situations of drug addiction (Das Thakur et al., 2013). Numerical studies presented in more detail in ’A simple form of drug addiction for resistant celllines‘ in Appendix 1 show that under dosedependent costs, a drug treatment only applied when the number of nonresistant cells exceeds the number of resistant cells (e.g., a metronomic therapy [Fischer et al., 2015]) leads to slower longterm tumour growth than does a constant therapy.
Postdiagnostic interventions
We next investigated how a postdiagnostic measure (usually some form of chemotherapy or radiation therapy, but could also involve adjuvants after an initial therapy) affects the probability of treatment success, the distribution of times for tumour relapse, and resistance levels. We assume that a tumour grows from one cell (i = 0, j = 0) and is discovered either at 10^{9} (early) or 10^{11} (very late) cells, whereupon the primary tumour is removed, leaving a small number (10^{4} or 10^{6}) of residual, and/or undetected or inoperable neighbouring micrometastatic cells, and/or distant metastatic cells. Below, we contrast this with prevention without discriminating the age at which either intervention type commences, whereas in the following section, we consider these as competing alternatives. Figure 3A and Figure 3—figure supplement 1A present the distributions of driver mutations for each scenario. (Recall that in the previous section, we assumed that when a measure commenced, tumours had no additional drivers (i = 0)).
First, we examine the case where postdiagnostic resection leaves 10^{6} cells. As suggested by our studies above on prevention, 1 million cells have a high probability of already containing resistant subclones, and deterministic effects dominate subsequent tumour growth dynamics. Comparing the median expectations of years from tumour excision to relapse, early discovery (at 10^{9} cells) yields an additional 3.4 years compared to late discovery (at 10^{11} cells) at σ = 1.5% (medians for low vs high detection thresholds are 14.8 and 11.4 years, respectively; Figure 3B). Consider the following example: 20 years after resection and commencing treatment, the probability of tumour nondetection (i.e., the tumour is either eradicated or does not reach the detection threshold) is close to zero, regardless of treatment intensity (Figure 3C). Contrast this with cases of prevention starting at the same cancer cell population size (10^{6} cells) but which fail to control the incipient tumour for the 50 years of the simulation: the detection time of these potentially lifethreatening tumours is substantially longer than either of the excision cases (median 25.5 years for σ = 1.5%, i.e., 0.3–0.4% potential cell arrest per day), and tumours are managed below the detection threshold after 20 years in more than 80% of cases for any σ > 1.0% (Figure 3C).
Now consider a residual population of 1/100th the previous case, that is, 10^{4} cells. Here, stochastic effects play a more important role in dynamics (Figure 3—figure supplement 1A,B). Due to initial heterogeneity (i.e., the cooccurrence of many subclones), when there are 4 and 5 (5 and 6) additional drivers in the dominant subclones of a residual cancer from an excised tumour of 10^{9} (10^{11}) cells, we observe a double peak at 4s and 5s (5s and 6s) (cf Figure 3—figure supplement 1B). These peaks in variability of outcomes are a result of the stochastic nature of the appearance of the first resistance mutations and of additional driver mutations. Interestingly, the secondary detection times (i.e., when residual or metastatic cells grow to form a new tumour) are more variable for small initial tumours compared to larger ones (cf the median 35.8 years, 90% CIs [17.0, 70.5] years vs 22.4, [13.7, 37.0] years for 10^{9} vs 10^{11}, respectively, with σ = 1.5%). This effect is due to resistance emergence in more aggressive subclones for larger tumours, such that the tumour relapses more deterministically (i.e., with less variability and faster on average). The probability of tumour nondetection after 20 years and the distribution of the mean number of accumulated drivers within tumours are shown in Figure 3—figure supplement 1C,D, respectively (cf with the previous case, shown in Figure 3C,D).
Importantly, for both thresholds of tumour excision, subsequent cancer cell arrest levels beyond approximately σ = 1.5% make little difference in terms of tumour growth (Figure 3BD, Figure 3—figure supplement 1BD), since virtually all of the sensitive cells postexcision will be arrested or killed by the measure beyond this level, leaving uncontrollable resistant cells to grow and repopulate the primary tumour site and/or metastases. (Note that this level is above that found in the previous section. This is because drivers accumulate throughout tumour growth in the results given in Figure 3, whereas tumours were assumed to only start accumulating the first drivers after growth from M_{0} cells in Figure 2 and Figure 2—figure supplements 1, 2). Moreover, we find that for postdiagnostic interventions knowledge about the number of drivers at the time of tumour discovery is a far better predictor of outcome than information about the time from tumour initiation to discovery, and that increases in treatment intensity tend to decrease predictive accuracy (Figure 3—figure supplements 2–5).
Prevention vs postdiagnostic intervention
The above results consider preventive measures and postdiagnostic interventions as independent rather than alternative approaches. Thus, although prevention delays tumour growth for longer times on average than does postdiagnostic intervention, because prevention is always initiated before diagnosis, when considering the relative benefits and risks of each, the actual time gained by the former relative to the latter in terms of cancerfree life will be less than the differences reported in Figure 3B and Figure 3—figure supplement 1B.
Figure 4 presents a hypothetical comparative scenario of prevention vs postdiagnostic intervention. Prevention may either succeed without recurrence, or should the measure initially fail and a tumour be clinically detected, the patient has a ‘second chance’ whereby the tumour is resected and treatment continued (assumed at the same treatment intensity σ), either to a further relapse (failure) or nondetection (success) (Figure 4A). Compare this scenario with the more standard postdiagnostic resection followed by treatment, which either results in relapse or detectionfree life (Figure 4B). These numerical experiments assume the same starting point (time at which the cancer cell population equals M_{0}, and drivers and resistant subclones are present) for each tumour, and because of a ‘second chance’ following initial failure in prevention, are run for a maximum of 50 years after the starting point (same as the numerical studies in the previous section). We also assume, as before, that potential therapeutic resistance mechanisms to all intervention types are identical.
Figure 5 presents the comparative outcomes (see also Videos 4, 5). When prevention starts at (or tumour resection misses) relatively large cancer cell populations (1 million cells), only small comparative gains occur from higher cell arrest in terms of outright treatment success (Figure 5A), whereas interventions starting at much smaller cancer cell numbers (10,000) result in considerably greater outright success (Figure 5B). Looking at situations of relapse only for prevention vs postdiagnostic intervention, the former generally results in superior outcomes in terms of delaying tumour growth, particularly for large residual cell populations (cf Figure 5C,D). In contrast, for lower numbers of residual cells, some postdiagnostic resected tumours in the sample will be initially resistance free (cf Figure 5—figure supplement 1A,B). This, together with fewer accumulated drivers in the highest driver subclones, contributes to improved outcomes should relapse occur (Figure 5D) and overall treatment success at sufficiently high treatment intensities (Figure 5A,B,E,F). Importantly, resected tumours in both the prevention (when it initially fails) and postdiagnostic scenarios may contain numerous resistant cells (example of 0.25% daily cellular arrest: Figure 5—figure supplements 2, 3). Prior selection for resistance in initially failed prevention generally results in larger residual resistant cell populations than pretherapeutic residual populations in postdiagnostic situations (filled bars, cf captions A and B in Figure 5—figure supplements 2, 3), but smaller residual resistant cell populations than treatment failures following postdiagnostic resection (hatched bars, cf captions A and D in Figure 5—figure supplements 2, 3). Note that, as expected, secondary failures are associated with larger percentages of resistant subclones and a shift in the distributions towards more drivers (cf captions C and D in Figure 5—figure supplements 2, 3).
Figure 5E,F shows the distributions of detection times for all numerical experiments. We see that when both nonrelapse (Figure 5A) and relapse (Figure 5C) are taken into account for large cancer cell populations (1 million cells), treating preventively at levels beyond about 0.3% arrest per day increases median delays in detection times due to outright success (i.e., survival beyond 50 years) but has no effect on the lower 95th percentile (Figure 5E). (Although not shown, arrest beyond approximately 0.6% per day does not yield further gains). In contrast, postdiagnostic intervention improves only marginally beyond daily arrest levels of about 0.3% (Figure 5E). Figure 5F shows the corresponding results for smaller cancer cell populations (based on integrating the results in Figure 5B,D), whereby a high median probability of full success is obtained >0.1% and >0.3% daily arrest for prevention and postdiagnostic intervention, respectively (Figure 5F). Thus for both cell population levels, prevention generally results in better outcomes compared to postdiagnostic intervention.
Discussion
MTD chemotherapies present numerous challenges, a major one being the selection of resistant phenotypes, which are possible precursors for relapse (Gerlinger and Swanton, 2010). We mathematically and numerically investigated how the intensity of an anticancer measure, modelled as the arresting effect on a cancer cell population, resulted in success (i.e., either eradication or longterm tumour control) or failure (tumours growing beyond a threshold indicative of a life threatening cancer). Our central result is that beyond low impact thresholds—approximated by the Darwinian fitness of the subclone with the most driver mutations—little additional control is achieved when resistant subclones are present or likely to emerge during the longterm intervention assumed here.
We considered two contrasting scenarios. In the first, people at high risk of contracting a life threatening cancer make lifestyle changes or receive continuous, chemopreventive therapies, and in the second, more usual situation, a tumour is discovered and removed, and the patient treated with specific cytotoxic or cytostatic chemicals and/or with radiation. We found that, as expected, to achieve a given outcome, prevention requires smaller effects on cancer cell populations of a given size than do postdiagnostic interventions, the latter having smaller probabilities of complete cure and shorter times to tumour relapse. Inversely and importantly, for any given cell arrest level, prevention is, on average, superior to comparable postdiagnostic interventions, even when including cases where prevention initially fails, and resection and additional therapy are needed.
Specifically, based on empirical parameter estimates, we find that maximal longterm control occurs at surprisingly low daily levels of arrest. In the example where interventions target 1 million cancer cells, these levels are approximately 0.6% and 0.3% for preventive and postdiagnostic interventions, respectively. That the level is higher for preventive scenarios is because effective ‘cure’ (i.e., relapse does not occur during the 50 year period assumed in our numerical experiments) is possible, especially at cell arrest levels beyond 0.3%, whereas ‘cure’ is far less probable for postdiagnostic interventions. However, should prevention initially fail and a tumour be diagnosed and resected, any residual or metastatic cells are likely to contain more resistant clones than the corresponding situation for a postdiagnostic tumour. We stress that this latter result is contingent on our assumption that the same mutations (and mechanisms) are responsible for resistance to both preventive and postdiagnostic interventions. Should preventive and postdiagnostic measures differ substantially in their targets (and therefore resistance mechanisms), then evolved resistance to (failed) prevention could be irrelevant to the efficacy of subsequent traditional therapies.
Our results point to what is perhaps an underappreciated challenge in cancer control: low impact interventions risk being unable to control subclones with the most fitnessenhancing drivers, whereas high levels of arrest risk selecting for resistance (Figure 6). Future models should investigate these contingencies more extensively for alternative assumptions and a range of parameterizations for specific cancer types. Below, we discuss challenges to cancer management for both preventive and postdiagnostic scenarios.
Preventive interventions
Whereas primary prevention is becoming an increasingly significant approach in reducing risk of certain cancers (e.g., Colditz and Bohlke, 2014), chemopreventive therapies are uncommon, despite empirical support for their effects (William et al., 2009). Several theoretical and in vitro experimental studies indicate that chemoprevention can reduce risks of life threatening cancers. For example, Silva and colleagues (Silva et al., 2012) parameterized computational models to show how low doses of verapamil and 2deoxyglucose could be administered adaptively to promote longer tumour progression times. These drugs are thought to increase the costs of resistance and the competitive impacts of sensitive cells on resistant cancer cell subpopulations. However, some of the most promising results have come from studies employing nonsteroidal antiinflammatory drugs (NSAIDs), including experiments (IbrahimHashim et al., 2012), investigations of their molecular effects (Galipeau et al., 2007; Kostadinov et al., 2013), and their use (Cuzick et al., 2015). For example, Ibrahim and coworkers (IbrahimHashim et al., 2012) studied the action of NSAIDs and specifically sodium bicarbonate in reducing prostate tumours in male TRAMP mice (i.e., an animal model of transgenic adenocarcinoma of the mouse prostate). They showed that mice commencing the treatment at 4 weeks of age had significantly smaller tumour masses, and that more survived to the end of the experiment than either the controls or those mice commencing the treatment at an older age. Kostadinov et al. (2013) showed how NSAID use in a sample of people with Barrett's oesophagus is associated with reductions in somatic genomic abnormalities and their growth to detectable levels. It is noteworthy that it is not known to what extent reductions in cancer progression under NSAIDs are due to either cytotoxic or cytostatic effects or both. Although we do not explicitly model cytotoxic or cytostatic impacts, therapies curbing net growth rates but maintaining them at or above zero could be interpreted as resulting from the action of either cytotoxic and/or cytostatic processes. In contrast, therapies reducing net growth rates substantially below zero necessarily have a cytotoxic component. Our model, or modifications of it to explicitly include cytotoxic and cytostatic effects, could be used in future research to make predictions about optimal dose and start times to achieve acceptable levels of tumour control (or, e.g., the probability of a given tumour size and heterogeneity level by a given age).
Decisions whether or not to employ specific chemopreventive therapies carry with them the risk of a poorer outcome than would have been the case had another available strategy (or no treatment at all) been adopted (Esserman et al., 2004). This issue is relevant to situations where alterations in lifestyle, removal or treatment of precancerous lesions, or medications potentially result in unwanted side effects or induce new invasive neoplasms (e.g., Berrington de Gonzalez et al., 2011). Chemopreventive management prior to clinical detection would be most appropriate for individuals with genetic predispositions, familial histories, elevated levels of specific biomarkers, or riskassociated behaviours or lifestyles (Hemminki and Li, 2004; Lippman and Lee, 2006; Sutcliffe et al., 2009; William et al., 2009; Hochberg et al., 2013). Importantly, our approach presupposes that the danger a nascent, growing tumour presents is proportional to its size and (implicitly, all else being equal) a person's age. Due caution is necessary in interpreting our results, since studies have argued that metastatic potential rather than tumour size may be a better predictor of future survival (Hynes, 2003; Foulkes et al., 2010; Sethi and Kang, 2011). However, given the expectation that prevention typically confronts smaller, less heterogeneous neoplasms, which are less likely to have resistant clones and to have metastasised (Hochberg et al., 2013; Gerlinger et al., 2014), support our basic conclusion that prevention is generally a superior strategy in terms of cancerfree survival compared to postdiagnostic intervention.
Postdiagnostic interventions
Over the past decade, several alternative approaches to MTD have been proposed, where the objective is to manage rather than eradicate tumours (e.g., Maley et al., 2004; Komarova and Wodarz, 2005; Gatenby, 2009; Gatenby et al., 2009a, 2009b; Foo and Michor, 2010; Jansen et al., 2015). Tumour management attempts to limit cancer growth, metastasis, and reduce the probability of obtaining resistance mutations through, for example, microenvironmental modification, or competition with nonresistant cancer cell populations or with healthy cells. These approaches usually involve clinically diagnosed cancers: either inoperable tumours or residual or metastatic cancers after tumour excision. In the former situation, tumours are typically large enough in size to contain numerous resistance mutations. In many, if not most, cases, these neoplasms will have metastasized, meaning greater variability both in terms of phenotypes and potential resistance to chemotherapies, and in penetrance of therapeutic molecules to targeted tumour cells (Klein et al., 2002; Byrne et al., 2005). In contrast, the latter situation involves smaller, residual, or metastatic cancer cell populations, composed of high frequencies of resistant variants or dormant cells (Klein et al., 2002). According to our results, both scenarios are likely to involve populations with large numbers of accumulated driver mutations (or, although not considered in our study, fewer driver mutations but each with larger selective effect), which ostensibly contribute to the speed of relapse. Thus, management of clinically detected tumours need not only limit the proliferation and spread of refractory subpopulations but should also aim to control the growth of multidriver subclones (Figure 5—figure supplements 2, 3). In other words, in addition to actual resistance mutations (j = 1), subclones with q drivers will be effectively resistant to therapeutic interventions if q s ≫ σ (Figure 6).
We therefore suggest that the frequency distribution of driver mutations and the distribution of resistant subclones within a heterogeneous cancer cell population could be used to instruct decisions of the time course of treatment levels, with the aims of curbing tumour growth, metastasis, and resistance. We found that tumours typically achieve several additional driver mutations by the time they reach detection (Figure 3A; Figure 3—figure supplement 1A; Figure 5—figure supplements 2, 3), which approximates certain estimates (Stratton et al., 2009) but falls short of others (Sjoblom et al., 2006).
Conclusion
Our results indicate that the two most important variables in determining therapeutic outcome are (1) the size of the initial cancer cell population (i.e., when prevention commences and/or postdiagnosis, following resection), (2) associated tumour heterogeneity in terms of accumulated drivers, and the presence of resistance phenotypes. This highlights the importance of biomarkers as accurate indicators of otherwise undetectable malignancies (Roukos et al., 2007), and the accurate assessment of local or distant metastases (Pantel et al., 1999). We suggest that if orderofmagnitude estimates of cell populations and intratumour heterogeneity are possible, then low dose, continuous, constant approaches could be established that lower and possibly minimize risks of the emergence of future, lifethreatening cancers. According to our model, such options will generally be superior to more aggressive chemotherapies if therapeutic resistance is a risk factor.
The framework proposed here is sufficiently general to portray major events in different types of cancer with emphasis on solid tumours. However, some aspects of cancerous tumour growth are considered only implicitly, and further research is required to formulate more realistic models to include, for example, spatial aspects of tumour growth (Orlando et al., 2013), competition/cooperation between different subclones (Korolev et al., 2014), combinational (multidrug) resistance (Gillet and Gottesman, 2010; Bozic et al., 2013), drugaddiction, observed for example in certain melanomas (Das Thakur et al., 2013), or advantageous resistant mutations, observed in some leukemias (Michor et al., 2005). Moreover, future studies should investigate alternatives to the traditional postdiagnostic therapeutic scenarios considered here (e.g., molecularly targeted therapies [Yap, 2015]). Our study nevertheless predicts that the main hurdle to postdiagnostic MTD interventions remains resistant subclones, since beyond minimal impacts on the order of 0.3% per day for the larger of the two residual or metastatic cell populations simulated here (which are still very small by clinical diagnostic standards—c 1 mm^{3}), increased therapeutic intensity selects disproportionally for resistance and has negligible benefits in terms of delaying lifethreatening cancers.
Appendix 1
Meanfield approach
We use the meanfield approach (see for example, Krapivsky et al., 2010), which approximates the behaviour of a system consisting of many cells, so that the effects of stochasticity are averaged, and an intermediate state is described by a set of ordinary differential equations.
Master equations
We write master equations to track the probability P_{ij}(t) that a randomly chosen cell from a population of tumour cells is of type (i, j) at time t.
The temporal dynamics of probabilities P_{ij}(t), i = 0, 1, …, N, where N is the maximal number of additionally acquired drivers and j = 0, 1, are described by:
Here, the righthand side is a superposition of probabilistic in and outflows from different mutational states to the current one (i, j). The function ℙ_{ij} describes the growth of subclone (i, j) and is proportional to the probability P_{ij}(t), multiplied by the difference between fitness f_{ij} and its average value over the whole population $\overline{f}\left(t\right)={\displaystyle \sum}_{i,j}{f}_{ij}{P}_{ij}\left(t\right)$. Functions ${\mathbb{P}}_{ij}^{\left(u\right)}$ and ${\mathbb{P}}_{ij}^{\left(v\right)}$ represent the probabilistic flows of mutations. For ${\mathbb{P}}_{ij}^{\left(u\right)}$, a driver is added from class (i − 1, j) to (i, j) in proportion to the probability ${P}_{i1,j}\left(t\right)$, the probability of cell birth b_{i−1,j}, and the probability of a zero locus being chosen from N total loci consisting of (N − (i − 1)) other zero loci. A similar approach is used to define the outflow term for the probability from class (i, j) to (i + 1, j). The second term ${\mathbb{P}}_{ij}^{\left(v\right)}$ is the probability of mutating to therapeutic resistance (i, j = 0) to (i, j = 1) and is proportional to P_{i0}(t) and birth rate b_{i0}. Finally, all terms are summed, taking into account the initial conditions: P_{00}(0) = 1 − κ, P_{01}(0) = κ, and P_{ij} = 0 for any other i or j.
The above elements lead to the following system of ordinary differential equations (ODEs):
where some probabilities P_{ij}(t) could, theoretically, take on negative values, for example, P_{−1,j}(t), when i = 0, in which case, they are set to zero.
A simple transformation,
allows omitting the term $\overline{f}\left(t\right)\hspace{0.17em}$ from Equation 1 and to linearize the latter with respect to the new ‘transformed’ probabilities p_{ij}(t). This gives:
where, for convenience, we write (jp_{i,j−1}(t) + (j − 1)p_{ij}(t)) instead of (1 − 2j)p_{i0}(t).
Probability generating function approach
With Equation 2 we apply the probability generating function (p.g.f.) method (Gardiner, 2004; Assaf, 2010) to transform the system of (2N + 1) ODEs to a Hamilton–Jacobi (HJ) equation, that is, a first order partial differential equation.
We define the p.g.f. as the polynomial over all modified probabilities p_{ij}(t) of the form:
where ξ and η are the variables that can be viewed as the momentum of an auxiliary Hamiltonian system governing the leadingorder stochastic dynamics of the system (Elgart and Kamenev, 2004). Notice that the function G(ξ, η, t) is linear with respect to η.
Suppose that the function G(ξ, η, t) is defined. One can then obtain all characteristics of the stochastic process, such as the average tumour size n(t) and the average frequency n_{res}(t)/n(t) of resistant cells within a tumour. The former quantity is:
Using the normalization condition for the probability: $\sum}_{i,j}{P}_{ij}\left(t\right)=1$, we obtain:
and then:
where the initial tumour size n(0) = M_{0} is sufficiently large. The frequency of resistant cells is defined as follows:
Initial conditions yield p_{00}(0) = 1 − κ, p_{01}(0) = κ, and p_{ij}(0) = 0 for any other i and j, so that G(ξ, η, t = 0) = 1 − κ + κη.
To obtain the HJ equation related to the p.g.f. G(ξ, η, t), we multiply Equation 2 with ξ^{i}η^{j} and sum up all equations for i = 0, 1,…,N and j = 0, 1. After some algebra, we obtain:
where only terms of order greater than or equal to u, v are retained, meaning that terms composed of the products s, c, and u, v are omitted.
Equation 6 is solved by the method of characteristics such that the HJ equation is transformed into a system of ordinary differential equations (i.e., the system of characteristics, see e.g., Melikyan, 1998).
Timevaried treatment schedule
We find the characteristics for the variables ξ and η using (Equation 6):
where σ(t) is a given function of time.
The p.g.f. G(ξ, η, t) changes along the characteristic Equation 7 according to the following ODE:
which is straightforward to integrate. Indeed, if we use Equation 7, this yields dlnG = (s(N + 1) − c)dt + Ndlnξ + dlnη. Thus,
Recall that the quantity on the left hand side remains constant only along the characteristic curve (Equation 7).
To obtain G(ξ = 1, η = 1, t), we need to solve Equation 7 subject to ξ(t) = η(t) = 1 and find ξ(0) and η(0). Then, given the initial condition G(ξ(0),η(0),0) = 1 − κ + κη(0), κ is a level of resistance within a tumour (κ ∈ [0,1]), we can define G(ξ, η, t) using Equation 9.
Finally, we use Equation 4 to derive the dynamics of n(t). To obtain the mean frequency of resistant cells within a tumour, we first write ∂G/∂η, using Equation 9 with the right hand side implicitly dependent on η and then substitute it into Equation 5. (Note that time t is measured in cell cycles, which are assumed to be of 4 days on average. To derive all necessary equations with respect to the actual time, we need to divide t by the length of the cellcycle and substitute it in the equations.)
Constant treatment
We study the case for constant σ. Notice that this includes the case of no treatment (σ = 0).
First, we find the characteristics for the variables ξ and η. Namely, the solution of Equation 7 gives:
The subsequent substitution of Equation 10 into Equation 8 leads to:
Taking into account u, v ≪ s, c and assuming v ≪ σ − c, we simplify further and write its approximate form:
which can be also written in the form:
As expected Equation 11 is linear with respect to η.
Thus, we derive an analytical expression for the dynamics n(t). Namely, we use Equations 4 and 11 and substitute ξ = η = 1, to obtain:
Equation 12 is simplified for two limiting cases. In the early stages of tumour growth, the value n(t) changes according to a hyperexponential law:
while at later stages, the most aggressive subclone persists, being sensitive if σ < c (n(t) ∝ e^{s(N+1)t}) and resistant otherwise (n(t) ∝ e^{(s(N + 1) − c)t}).
To compute the frequency of resistant cells within a tumour (Equation 5), we derive ∂G/∂η using Equation 11:
so that:
Appendix 1—figure 1 shows the excellent correspondence between numerical experiments and analytical results for σ on the order of s. Appendix 1—figure 2 provides additional details on distribution of tumour sizes depending on the applied treatment intensity (points B and C).
Distribution of subclones within an exponentially growing tumour
The p.g.f. G(ξ, η, t) is used to derive expressions for all P_{ij}(t), which are the probabilities of selecting a cell of type (i, j) from a tumour at time moment t. Namely, we need to differentiate the p.g.f. with respect to ξ and η, so that:
where i = 0, 1,… and j = 0, 1. Thus, we write:
then:
The general formula is written as follows:
where i = 0, 1, …N, and the function:
defines the probability to pick a cell with i drivers independently of resistant status, ${P}_{i\ast}\left(t\right)\triangleq {P}_{i0}\left(t\right)+{P}_{i1}\left(t\right)$, where $\left(\begin{array}{c}N\\ i\end{array}\right)$ denotes a binomial coefficient, equal $\frac{N!}{i!\left(Ni\right)!}$.
The distribution P_{i∗}(t) for a particular case of N = 6 is shown in Appendix 1—figure 3.
We now derive the mean time period when a given subclone with i additionally accumulated drivers dominates within a tumour.
Defining the time moments t = t_{i} for which P_{i−1,∗}(t_{i}) = P_{i∗}(t_{i}) (i = 0, 1, 2,…,N) gives:
where we assume u ≪ s.
The time period when the subclone with i drivers prevails in a cell population is defined by the following expression:
where i ≠ 0. For i = 0, we have:
The latter formula has been previously reported (see Equation S7 in reference Bozic et al., 2010).
Varying mutation rate and initial tumour size
To understand better how the inflection points emerge around σ = qs (q = 1, 2, 3,…), we first consider a much simpler case than the main text. Suppose that no additional driver mutation is acquired during tumourigenesis, u = 0. Any treatment regime of constant intensity that lowers the selective advantage (σ < s) only slows tumour growth. In such cases, the median detection time increases with σ (see Figure 6). Assuming that resistance is not obtained, the median time to detection approaches a vertical asymptote at σ = s, whereas the tumour is always eradicated for σ > s. If v > 0, then the tumour relapses following the appearance of the resistance mutation, and the median detection time approaches the horizontal asymptote for σ ≫ s. Thus, the final result for the median detection time will be a line with an inflection point near σ = s, consisting of two effects: higher treatment levels resulting in the control of sensitive clones with ever higher numbers of drivers (blue colouring), and the lack of control of costly resistant clones (red colouring) (Figure 6).
In the general case (u > 0, v > 0), the median follows from the different elements cited above, consisting of several possible branches (e.g., Figure 2—figure supplement 1D) or none, where the latter case depends on the relation between the mutation rate u and the initial cell number M_{0} (e.g., for M_{0} = 10^{7} see Figure 2—figure supplement 1B).
Appendix 1—figure 4 shows an example. Panel A shows a case when u is varied and M_{0} remains fixed. We identify the key parameter for the appearance of the inflection points as M_{0}u. It defines the emergence probability of the next subclone with one additional driver. Hence, the inflection points are more apparent for smaller values of M_{0}u and vanish for larger values of M_{0}u. This same tendency can be seen in Figure 2—figure supplement 1B, where M_{0} is varied and u is fixed. Panels B, C, and D provide more details on the interplay between M_{0}u and the inflection points.
A simple form of drug addiction for resistant celllines
To explore the possible effects of drug addiction on tumour growth, we propose a simple modification of the fitness function. Suppose the cost of resistance C is given by the relation:
It equals c as before when no treatment is applied (σ = 0), while drug addiction increases with larger σ. The cost equals zero at σ = 2s and becomes negative for σ > 2s, implying that further drug administration has a beneficial effect on proliferation of resistant cells. Fischer and colleagues (Fischer et al., 2015) argue that under drug addiction, a metronomic treatment strategy is more beneficial than a constantly applied treatment. The metronomic strategy imposes a simple rule: treatment is only applied when the number of nonresistant cells exceeds the number of resistant cells.
We compare the originally studied model, where the resistant cells exhibit no drug addiction, with a modified case of resistant cell drug addiction. In the latter, we consider two different treatment regimes: a constantly administrated drug application and metronomic therapy. As an example, Appendix 1—figure 5 shows the occurrence drug addiction worsens treatment outcomes with 5% vs 31% eradicated tumours at a daily arresting effect of 0.25% (σ = 1.0%) for presence vs absence of drug addiction, respectively. Moreover, metronomic therapy results in a better outcome than a constantly administrated chemotherapy. For example, the former adds 6.6 additional years to the median detection time at σ = 1.0%, compared to the constant treatment with drug addiction, but loses 11.1 years, compared to the previous case of a constant treatment without drug addiction.
References

Exact solution of a twotype branching process: models of tumor progressionJournal of Statistical Mechanics 2011:P08018.https://doi.org/10.1088/17425468/2011/08/P08018

Theory of large fluctuations in stochastic populationsPhD thesis, Hebrew University of Jerusalem. http://guava.physics.uiuc.edu/∼assaf/thesis.pdf.

Impact of genetic dynamics and singlecell heterogeneity on development of nonstandard personalized medicine strategies for cancerProceedings of the National Academy of Sciences of USA 109:14586–14591.https://doi.org/10.1073/pnas.1203559109

Cancer evolution: mathematical models and computational inferenceSystematic Biology 64:e1–e25.https://doi.org/10.1093/sysbio/syu081

Accumulation of driver and passenger mutations during tumor progressionProceedings of the National Academy of Sciences of USA 107:18545–18550.https://doi.org/10.1073/pnas.1010978107

ColourBrew 2.0: color advice for cartographyColourBrew 2.0: color advice for cartography, Pennsylvania State University. http://colorbrewer2.org. Accessed 21.04.2014.

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)Journal of Cellular and Molecular Medicine 9:777–794.https://doi.org/10.1111/j.15824934.2005.tb00379.x

Mortality in relation to smoking: 20 years' observations on male British doctorsBritish Medical Journal 2:1525–1536.https://doi.org/10.1136/bmj.2.6051.1525

Rare event statistics in reactiondiffusion systemsPhysical Review. E, Statistical, Nonlinear, and Soft Matter Physics 70:041106.https://doi.org/10.1103/PhysRevE.70.041106

Applying the neoadjuvant paradigm to ductal carcinoma in situAnnals of Surgical Oncology 11:S28–S36.https://doi.org/10.1007/BF02524793

The value of monitoring to control evolving populationsProceedings of the National Academy of Sciences of USA 112:1007–1012.https://doi.org/10.1073/pnas.1409403112

Evolution of resistance to anticancer therapy during general dosing schedulesJournal of Theoretical Biology 263:179–188.https://doi.org/10.1016/j.jtbi.2009.11.022

Triplenegative breast cancerThe New England Journal of Medicine 363:1938–1948.https://doi.org/10.1056/NEJMra1001389

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicineBritish Journal of Cancer 103:1139–1143.https://doi.org/10.1038/sj.bjc.6605912

Cancer: evolution within a lifetimeAnnual Review of Genetics 48:215–236.https://doi.org/10.1146/annurevgenet120213092314

Mechanisms of multidrug resistance in cancerMethods in Molecular Biology 596:47–76.https://doi.org/10.1007/9781607614166_4

A unifying theory of carcinogenesis, and why targeted therapy doesn't workEuropean Journal of Radiology 81:S48–S50.https://doi.org/10.1016/S0720048X(12)700189

Does everyone develop covert cancer?Nature Reviews. Cancer 14:209–210.https://doi.org/10.1038/nrc3703

Familial risk in testicular cancer as a clue to a heritable and environmental aetiologyBritish Journal of Cancer 90:1765–1770.https://doi.org/10.1038/sj.bjc.6601714

Preventive evolutionary medicine of cancersEvolutionary Applications 6:134–143.https://doi.org/10.1111/eva.12033

Systemic buffers inhibit carcinogenesis in TRAMP miceThe Journal of Urology 188:624–631.https://doi.org/10.1016/j.juro.2012.03.113

Evolution of resistance during clonal expansionGenetics 172:2557–2566.https://doi.org/10.1534/genetics.105.049791

Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancerProceedings of the National Academy of Sciences USA 112:937–938.https://doi.org/10.1073/pnas.1420297111

Large population solution of the stochastic LuriaDelbruck evolution modelProceedings of the National Academy of Sciences of USA 110:11682–11687.https://doi.org/10.1073/pnas.1309667110

Drug resistance in cancer: principles of emergence and preventionProceedings of the National Academy of Sciences of USA 102:9714–9719.https://doi.org/10.1073/pnas.0501870102

Turning ecology and evolution against cancerNature Reviews. Cancer 14:371–380.https://doi.org/10.1038/nrc3712

The path of least resistance: aggressive or moderate treatment?Proceedings. Biological Sciences/The Royal Society 281:20140566.https://doi.org/10.1098/rspb.2014.0566

Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivityCancer Epidemiology, Biomarkers & Prevention 13:1375–1384.

Intratumour heterogeneity: a looking glass for cancer?Nature Reviews. Cancer 12:323–334.https://doi.org/10.1038/nrc3261

Impact of deleterious passenger mutations on cancer progressionProceedings of the National Academy of Sciences of USA 110:2910–2915.https://doi.org/10.1073/pnas.1213968110

BookGeneralized characteristics of first order partial differential equationsBoston: Birkhäuser.

Detection and clinical importance of micrometastatic diseaseJournal of the National Cancer Institute 91:1113–1124.https://doi.org/10.1093/jnci/91.13.1113

SoftwareR project for statistical computing, version R package version 2.15.3R project for statistical computing.

The effect of one additional driver mutation on tumor progressionEvolutionary Applications 6:34–45.https://doi.org/10.1111/eva.12020

Exact solution of the Eigen model with general fitness functions and degradation ratesProceedings of the National Academy of Sciences of USA 103:4935–4939.https://doi.org/10.1073/pnas.0504924103

Unravelling the complexity of metastasis—molecular understanding and targeted therapiesNature Reviews. Cancer 11:735–748.https://doi.org/10.1038/nrc3125

Cancer chemoprevention: a rapidly evolving fieldBritish Journal of Cancer 109:1–7.https://doi.org/10.1038/bjc.2013.280

Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic reviewHealth Technology Assessment 13:1–219.https://doi.org/10.3310/hta13050

Molecular targets for cancer chemopreventionNature Reviews. Drug Discovery 8:213–225.https://doi.org/10.1038/nrd2663

Can loss of apoptosis protect against cancer?Trends in Genetics 23:232–237.https://doi.org/10.1016/j.tig.2007.03.005

An intermittent approach for cancer chemopreventionNature Reviews. Cancer 11:879–885.https://doi.org/10.1038/nrc3167
Decision letter

Carl T BergstromReviewing Editor; University of Washington, United States
eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.
Thank you for sending your work entitled “Dynamics of preventive and reactive cancer control using lowimpact measures” for consideration at eLife. Your article has been favorably evaluated by Diethard Tautz (Senior editor) and three reviewers, one of whom, Carl Bergstrom, is a member of our Board of Reviewing Editors.
The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.
All three reviewers found this to be an interesting and timely paper that addresses a very important question. The work is wellconceived, attentive to detail, and wellinterpreted. Nonetheless the reviewers raised a number of points which they felt should be addressed.
1) The authors use specific parameter values for their investigations. These parameters are presented in Table 1, and instead of giving biologically applicable ranges, the authors use particular values. In my opinion, it is important to investigate the range and not just a set of values. The paper would benefit greatly from some degree of sensitivity analysis to explain how results change as parameters change. For example, it is assumed that mutations are acquired with the rate 3.4x10^(^{5}). In reality, this parameter can vary over a very large range. It could be as low as 10^(^{7}) and as high as 10^(^{2}) in the presence of genomic instability. This is a change over five orders of magnitude, and can affect the results in a significant way. This should be addressed and discussed.
2) The authors assume that resistance presents a cost. At the same time, it has been suggested in the literature that some resistant mutations can actually be advantageous (e.g. in chronic lymphocytic leukemia). How will this alter the results?
3) It would be useful to discuss how the model applies or could be modified to apply to different types of therapies. Traditional therapies, more modern targeted therapies, and various sorts of combination treatments have very different properties. Often the source of resistance is not known. It is sometimes associated with specific mutations, and sometimes it has a different origin. The authors should explain how their model can be used in these different circumstances, and what modifications in the model correspond to different cases. Here we are looking less for additional modeling than for guidance on how the model could be adapted in future work.
4) Similarly, different cancers have different properties (solid tumors vs. leukemias, for example). It would be useful to discuss how future studies could extend the model to explicitly model different cancer types.
5) In the Abstract and throughout the paper, please clearly specify whether this paper is intended to address the implications of preventive/therapeutic interventions on the fate of a single aberrant clone, or on the fate of an individual patient. This distinction is important because cancer at almost any site in the body occurs in the context of additional subclinical aberrations in the population of cells. That is, most cancers arise in organs that are predisposed to cancer due to an interplay of inherited and exogenous influences (i.e., gene x environment interactions). Thus the process can be manifest not only in a single aberrant clone in one organ, but many concomitant clones within or across organs (e.g., longterm tobacco exposure places one at risk for myriad cancers in various organs) leading to synchronous and metachronous precancers and cancers.
6) The manuscript continually refers to “residual cells,” but the goal of most cancerrelated surgeries is complete tumor removal. Complete resection is the foundation of cancer care wherever feasible. So it appears that this paper really relates to the fraction of cancer cases with residual or metastatic cancer. If so, that should be clarified in the title and background of the work (e.g. Dynamics of preventive and therapeutic interventions in patients with residual/metastatic cancer using lowimpact measures).
https://doi.org/10.7554/eLife.06266.030Author response
1) The authors use specific parameter values for their investigations. These parameters are presented in Table 1, and instead of giving biologically applicable ranges, the authors use particular values. In my opinion, it is important to investigate the range and not just a set of values. The paper would benefit greatly from some degree of sensitivity analysis to explain how results change as parameters change. For example, it is assumed that mutations are acquired with the rate 3.4x10^(^{5}). In reality, this parameter can vary over a very large range. It could be as low as 10^(^{7}) and as high as 10^(^{2}) in the presence of genomic instability. This is a change over five orders of magnitude, and can affect the results in a significant way. This should be addressed and discussed.
We used a canonical set of parameters, many based on biologically grounded estimates. We did in fact conduct sensitivity analyses for several of the most important parameters (e.g., Figure 2 and its supplements). In reply to the reviewer’s request, we have now added an additional column to Table 1, indicating plausible ranges for parameter values, based on the literature. In addition, we conducted further sensitively analyses by varying mutation rates, finding that tumors exhibit more or less deterministic growth depending on the relation between the initial number of cells and additional driver mutation rate. This is analogous to the phenomenon shown in Figure 2–figure supplement 1D, whereby the higher the mutation rate, the less apparent are stochastic effects. The corresponding analysis is presented in Section B of Appendix 1 (see also Figure 5). This is referenced by a paragraph in the Results, in the Preventive measures section.
2) The authors assume that resistance presents a cost. At the same time, it has been suggested in the literature that some resistant mutations can actually be advantageous (e.g. in chronic lymphocytic leukemia). How will this alter the results?
This is a good point, and we agree that no cost, or more extreme situations such as drug addiction in resistant celllines (e.g., in certain melanomas (Das Thakur et al., 2014) or in leukemias (Michor et al., 2005), is important to consider for tumor management. Establishing optimized schedules in such situations is an intriguing problem that we plan to study in more detail in the future. In reply to the reviewers’ comment, we considered how drug addiction might alter our results. See Section C of Appendix 1. The corresponding paragraph in the main text is added to the end of the Results, Preventive measures section,. We also added two references (Das Thakur et al., 2014 and Fischer, VásquezGarcía and Mustonen, 2015).
3) It would be useful to discuss how the model applies or could be modified to apply to different types of therapies. Traditional therapies, more modern targeted therapies, and various sorts of combination treatments have very different properties. Often the source of resistance is not known. It is sometimes associated with specific mutations, and sometimes it has a different origin. The authors should explain how their model can be used in these different circumstances, and what modifications in the model correspond to different cases. Here we are looking less for additional modeling than for guidance on how the model could be adapted in future work.
Our current discussion does discuss cytotoxic vs. cytostatic effects (please see the subsection headed “Preventive interventions”). Although we agree that discussing model extensions to other types of therapy would be useful, it is unclear without actually modifying the model how these would alter the results, and as such we simply mention the importance of future study to consider these alternatives (in our Conclusion, we state: “Moreover, future studies should also investigate alternatives to the traditional postdiagnostic therapeutic scenarios considered here [e.g., molecularly targeted therapies (Yap, 2015)]”). We do however think it is important to stress the mutational basis for resistance, and as such have added text in the Discussion.
4) Similarly, different cancers have different properties (solid tumors vs. leukemias, for example). It would be useful to discuss how future studies could extend the model to explicitly model different cancer types.
The second paragraph of the Conclusions now provides a series of possible modifications that can be made to our model to consider different cancer types and levels of resolution. Necessary references were also added.
5) In the Abstract and throughout the paper, please clearly specify whether this paper is intended to address the implications of preventive/therapeutic interventions on the fate of a single aberrant clone, or on the fate of an individual patient. This distinction is important because cancer at almost any site in the body occurs in the context of additional subclinical aberrations in the population of cells. That is, most cancers arise in organs that are predisposed to cancer due to an interplay of inherited and exogenous influences (i.e., gene x environment interactions). Thus the process can be manifest not only in a single aberrant clone in one organ, but many concomitant clones within or across organs (e.g., longterm tobacco exposure places one at risk for myriad cancers in various organs) leading to synchronous and metachronous precancers and cancers.
http://tiny.cc/AkhmHoch15SVideos45We now clarify that we are examining the simple situation of the fate of an individual patient confronted with single cancer. We have added text to the Abstract and Introduction clarifying this, and at the end of the Discussion stressed that future models should consider multiple independent or correlated events (same or different organs).
6) The manuscript continually refers to “residual cells,” but the goal of most cancerrelated surgeries is complete tumor removal. Complete resection is the foundation of cancer care wherever feasible. So it appears that this paper really relates to the fraction of cancer cases with residual or metastatic cancer. If so, that should be clarified in the title and background of the work (e.g. Dynamics of preventive and therapeutic interventions in patients with residual/metastatic cancer using lowimpact measures).
Prevention in our model acts on cancers before they are detected. What we now call “postdiagnostic interventions” (“reactive measures” in the original manuscript) involve resection followed by treatment. We assume that either resection itself is not perfect, and/or neighboring micrometastases exist, and/or distant metastases are present, but undetected or nonremovable. We show how the population number and (epi)genetic composition (in terms of drivers and resistance) of residual cells can have a major impact on both preventive (but initially failed) and postdiagnostic interventions (Figure 6A, C, E vs. Figure 6B, D, F). We now clarify this in the manuscript (please see the Introduction and the subsections entitled “Postdiagnostic interventions” and “Prevention vs. postdiagnostic intervention”).
https://doi.org/10.7554/eLife.06266.031Article and author information
Author details
Funding
Institut national de la santé et de la recherche médicale (CanEvolve PC201306)
 Michael E Hochberg
Agence Nationale de la Recherche (EvoCan ANR13BSV70003001)
 Michael E Hochberg
Centre National de la Recherche Scientifique (PICS 05313)
 Michael E Hochberg
Réseau National des Systèmes Complexes (RNSC 2012)
 Michael E Hochberg
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
The authors are grateful to Athena Aktipis, Daniel Fisher, Sylvain Gandon, Urszula Hibner, Natalia Komarova, Patrice Lassus, Carlo Maley, Ville Mustonen, Robert Noble and anonymous referees for comments. All calculations were made using programs, written in C, and the free, opensource statistical package R (R Development Core Team, 2014). The colour palette for figures was adopted from ColorBrewer 2.0 (Brewer and Harrower, 2013). Code for all calculations, and for producing all of the figures, is available at http://tiny.cc/AkhmHoch15Scripts and can be used freely for noncommercial purposes. The work was made possible by the facilities of the Shared Hierarchical Academic Research Computing Network (SHARCNET:www.sharcnet.ca) and Compute/Calcul Canada. ARA was supported by CNRS Interdisciplinary postdoctoral program. MEH thanks ITMO ‘Physique Cancer’ (CanEvolve PC201306), ANR (EvoCan ANR13BSV7000301) and PICS (PlCS05313) for financial support.
Reviewing Editor
 Carl T Bergstrom, University of Washington, United States
Publication history
 Received: December 27, 2014
 Accepted: June 24, 2015
 Accepted Manuscript published: June 25, 2015 (version 1)
 Version of Record published: August 5, 2015 (version 2)
Copyright
© 2015, Akhmetzhanov and Hochberg
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics

 1,308
 Page views

 232
 Downloads

 6
 Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Further reading

 Computational and Systems Biology
 Epidemiology and Global Health
The endocannabinoid system consists mainly of 2arachidonoylglycerol and anandamide, as well as cannabinoid receptor type 1 (CB1) and type 2 (CB2). Based on previous studies, we hypothesized that a circulating peptide previously identified as Osteogenic Growth Peptide (OGP) maintains a boneprotective CB2 tone. We tested OGP activity in mouse models and cells, and in human osteoblasts. We show that the OGP effects on osteoblast proliferation, osteoclastogenesis, and macrophage inflammation in vitro, as well as rescue of ovariectomyinduced bone loss and prevention of ear edema in vivo are all abrogated by genetic or pharmacological ablation of CB2. We also demonstrate that OGP binds at CB2 and may act as both an agonist and positive allosteric modulator in the presence of other lipophilic agonists. In premenopausal women, OGP circulating levels significantly decline with age. In adult mice, exogenous administration of OGP completely prevented agerelated bone loss. Our findings suggest that OGP attenuates agerelated bone loss by maintaining a skeletal CB2 tone. Importantly, they also indicate the occurrence of an endogenous peptide that signals via CB2 receptor in health and disease.

 Cancer Biology
 Computational and Systems Biology
Late advances in genome sequencing expanded the space of known cancer driver genes severalfold. However, most of this surge was based on computational analysis of somatic mutation frequencies and/or their impact on the protein function. On the contrary, experimental research necessarily accounted for functional context of mutations interacting with other genes and conferring cancer phenotypes. Eventually, just such results become 'hard currency' of cancer biology. The new method, NEAdriver employs knowledge accumulated thus far in the form of global interaction network and functionally annotated pathways in order to recover known and predict novel driver genes. The driver discovery was individualized by accounting for mutations' cooccurrence in each tumour genome  as an alternative to summarizing information over the whole cancer patient cohorts. For each somatic genome change, probabilistic estimates from two lanes of network analysis were combined into joint likelihoods of being a driver. Thus, ability to detect previously unnoticed candidate driver events emerged from combining individual genomic context with network perspective. The procedure was applied to ten largest cancer cohorts followed by evaluating error rates against previous cancer gene sets. The discovered driver combinations were shown to be informative on cancer outcome. This revealed driver genes with individually sparse mutation patterns that would not be detectable by other computational methods and related to cancer biology domains poorly covered by previous analyses. In particular, recurrent mutations of collagen, laminin, and integrin genes were observed in the adenocarcinoma and glioblastoma cancers. Considering constellation patterns of candidate drivers in individual cancer genomes opens a novel avenue for personalized cancer medicine.